BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Colombelli F, Kowalski TW, Recamonde-mendoza M. A hybrid ensemble feature selection design for candidate biomarkers discovery from transcriptome profiles. Knowledge-Based Systems 2022;254:109655. [DOI: 10.1016/j.knosys.2022.109655] [Reference Citation Analysis]
2 Khan SA, Lee TKW. Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking. Front Pharmacol 2022;13:968148. [DOI: 10.3389/fphar.2022.968148] [Reference Citation Analysis]
3 Man KF, Ma S. Mechanisms of resistance to tyrosine kinase inhibitors in liver cancer stem cells and potential therapeutic approaches. Essays Biochem 2022:EBC20220001. [PMID: 35818992 DOI: 10.1042/EBC20220001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Batool S, Javed MR, Aslam S, Noor F, Javed HMF, Seemab R, Rehman A, Aslam MF, Paray BA, Gulnaz A. Network Pharmacology and Bioinformatics Approach Reveals the Multi-Target Pharmacological Mechanism of Fumaria indica in the Treatment of Liver Cancer. Pharmaceuticals 2022;15:654. [DOI: 10.3390/ph15060654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zheng T, Zhang X, Wang Y, Wang A. SPOCD1 regulated by miR-133a-3p promotes hepatocellular carcinoma invasion and metastasis. J Int Med Res 2022;50:030006052110537. [DOI: 10.1177/03000605211053717] [Reference Citation Analysis]
6 Arzumanian VA, Kiseleva OI, Poverennaya EV. The Curious Case of the HepG2 Cell Line: 40 Years of Expertise. Int J Mol Sci 2021;22:13135. [PMID: 34884942 DOI: 10.3390/ijms222313135] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Yao Z, Wen S, Luo J, Hao W, Liang W, Chen Y. Establishment and Validation of an MTORC1 Signaling-Related Gene Signature to Predict Overall Survival in Patients with Hepatocellular Carcinoma. Biomed Res Int 2021;2021:6299472. [PMID: 34853791 DOI: 10.1155/2021/6299472] [Reference Citation Analysis]
8 Setayesh T, Colquhoun SD, Wan YY. Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma. Liver Res 2020;4:173-9. [PMID: 34567824 DOI: 10.1016/j.livres.2020.11.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Dolicka D, Foti M, Sobolewski C. The Emerging Role of Stress Granules in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:9428. [PMID: 34502337 DOI: 10.3390/ijms22179428] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 He RQ, Li JD, Du XF, Dang YW, Yang LJ, Huang ZG, Liu LM, Liao LF, Yang H, Chen G. LPCAT1 overexpression promotes the progression of hepatocellular carcinoma. Cancer Cell Int 2021;21:442. [PMID: 34419067 DOI: 10.1186/s12935-021-02130-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
14 Sung PS, Han JW, Seo C, Ahn J, Lee SK, Nam HC, Choi HJ, You YK, Jang JW, Choi JY, Yoon SK. Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant. Front Pharmacol 2021;12:685176. [PMID: 34326770 DOI: 10.3389/fphar.2021.685176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
16 Patel A, Perl A. Redox Control of Integrin-Mediated Hepatic Inflammation in Systemic Autoimmunity. Antioxid Redox Signal 2021. [PMID: 34036799 DOI: 10.1089/ars.2021.0068] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Jeoung NH, Jeong JY, Kang BS. Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation. J Cancer Prev 2021;26:145-52. [PMID: 34258253 DOI: 10.15430/JCP.2021.26.2.145] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Peruhova M, Peshevska-sekulovska M, Panayotova G, Velikova T. Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy. Gastroenterology Insights 2021;12:283-92. [DOI: 10.3390/gastroent12030025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zhao X, Wang J, Deng Y, Liao L, Zhou M, Peng C, Li Y. Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism. Phytother Res 2021. [PMID: 34159683 DOI: 10.1002/ptr.7104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wei J, Ye L, Song L, Tang H, Zhang T, Fu B, Zhang Y, Yang Q, Yang Y, Yi S. TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of Hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1074-85. [PMID: 34295558 DOI: 10.21037/jgo-20-378] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Adelani IB, Rotimi OA, Maduagwu EN, Rotimi SO. Vitamin D: Possible Therapeutic Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:642653. [PMID: 34113565 DOI: 10.3389/fonc.2021.642653] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
22 Wu BK, Chen QH, Pan D, Chang B, Sang LX. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. Int Immunopharmacol 2021;96:107790. [PMID: 34162153 DOI: 10.1016/j.intimp.2021.107790] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
23 Yang JR, Ling XL, Guan QL. RAP2A promotes apoptosis resistance of hepatocellular carcinoma cells via the mTOR pathway. Clin Exp Med 2021. [PMID: 34018090 DOI: 10.1007/s10238-021-00723-x] [Reference Citation Analysis]
24 Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L, Xie Y, Zhou S, Cao W, Tang X. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Mol Med Rep 2021;24:508. [PMID: 33982772 DOI: 10.3892/mmr.2021.12147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Melnik BC. Dairy consumption and hepatocellular carcinoma risk. Ann Transl Med 2021;9:736. [PMID: 33987434 DOI: 10.21037/atm-2020-ubih-06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhang H, Xu H, Tang Q, Bi F. The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells. Anticancer Drugs 2021;32:793-801. [PMID: 33675613 DOI: 10.1097/CAD.0000000000001067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Mroweh M, Roth G, Decaens T, Marche PN, Lerat H, Macek Jílková Z. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:1794. [PMID: 33670268 DOI: 10.3390/ijms22041794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
28 Meng W, Meng J, Jiang H, Feng X, Wei D, Ding Q. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway. Anal Cell Pathol (Amst) 2020;2020:6021602. [PMID: 33354489 DOI: 10.1155/2020/6021602] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Kaneya Y, Takata H, Wada R, Kure S, Ishino K, Kudo M, Kondo R, Taniai N, Ohashi R, Yoshida H, Naito Z. Inhibitor for protein disulfide-isomerase family A member 3 enhances the antiproliferative effect of inhibitor for mechanistic target of rapamycin in liver cancer: An in vitro study on combination treatment with everolimus and 16F16. Oncol Lett 2021;21:28. [PMID: 33240434 DOI: 10.3892/ol.2020.12289] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Cho CS, Kowalsky AH, Lee JH. Pathological Consequences of Hepatic mTORC1 Dysregulation. Genes (Basel) 2020;11:E896. [PMID: 32764389 DOI: 10.3390/genes11080896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Han W, Shi J, Cao J, Dong B, Guan W. Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma. Onco Targets Ther 2020;13:6937-55. [PMID: 32764985 DOI: 10.2147/OTT.S260376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]